NEW YORK – Estrella Immunopharma's first trial of its CD19-directed autologous T-cell therapy for non-Hodgkin's lymphoma is progressing smoothly, the company said late last week, and it has moved on ...

The company is eyeing deals less than $2 billion, saying it has enough internal assets to replace losses from generic ...

Researchers at the Broad Institute, Jackson Laboratory, and Boston Children's Hospital will treat rare disease patients and ...

It is also preclinically testing three RNA vaccines — one for cytomegalovirus-driven colorectal cancer, glioblastoma, and triple-negative breast cancer, a second for HPV-positive head and neck cancers ...

After a promising Phase I read out on mKRAS-VAX in patients with hereditary cancer predisposition and pancreatic lesions, ...

The approval was based on the Phase III SERENA-6 trial that used ctDNA testing to detect ESR1 resistance mutations and inform treatment switching.

A Children's Hospital of Philadelphia team said their case study highlighted the need for increased safety monitoring.

The firm reported that two Phase III trials of Redemplo met their primary endpoints of lowering patients' triglyceride levels.

A deal with Regeneron announced in April could push the firm's revenue and income totals past $1 billion by year end.

The biotech plans to use the proceeds to develop its pipeline of in vivo CRISPR-based genetic medicines for cardiometabolic disease, including STX-1150.

The firm will use the funding to begin a pivotal study of its EGFR inhibitor, advance the Phase I study of its CLK inhibitor, and develop its preclinical pan-KRAS program.

The results presented at AAIC had been highly anticipated since Biogen said it would advance the drug despite missing a Phase ...